Abrégé

A clinical support system comprises a processor and a display component, wherein: the processor is configured to: receive image data, the image data representing an image of a plurality of cells obtained from a human or animal subject, the image data comprising a plurality of subsets of image data, each subset comprising data representing a portion of the image data corresponding to a respective cell of the plurality of cells; apply a trained deep learning neural network model to each subset of the image data, the deep learning neural network model comprising: a plurality of convolutional neural network layers each comprising a plurality of nodes; and a bottleneck layer comprising no more than ten nodes, wherein the processor is configured to apply the trained deep learning neural network model to each subset of the image data by applying the plurality of CNN layers, and subsequently applying the bottleneck layer, each node of the bottleneck layer of the machine-learning model configured to output a respective activation value for that subset of the image data; for each subset of the image data, derive a dataset comprising no more than three values, the values derived from the activation values of the nodes in the bottleneck layer; and generate instructions, which when executed by the display component of a clinical support system, cause the display component of the computer to display a plot in no more than three dimensions of the respective dataset of each subset of the image data. Associated computer-implemented methods, including for training the deep learning neural network model, are provided.

Classes IPC  ?

• G06V 20/69 - Objets microscopiques, p.ex. cellules biologiques ou pièces cellulaires
• G06T 7/00 - Analyse d'image
• G06T 11/20 - Traçage à partir d'éléments de base, p.ex. de lignes ou de cercles
• G06V 10/774 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant l’intégration et la réduction de données, p.ex. analyse en composantes principales [PCA] ou analyse en composantes indépendantes [ ICA] ou cartes auto-organisatrices [SOM]; Séparation aveugle de source méthodes de Bootstrap, p.ex. "bagging” ou “boosting”
• G06V 10/82 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant les réseaux neuronaux
• G16B 15/00 - TIC spécialement adaptées à l’analyse de structures moléculaires bidimensionnelles ou tridimensionnelles, p.ex. relations structurelles ou fonctionnelles ou alignement de structures
• G16B 40/20 - Analyse de données supervisée

Abrégé

Detection of abnormality in specimen image A computer-implemented method of detecting the presence of morphologically abnormal cells in a specimen image comprises: receiving electronic image data representative of a specimen image, the specimen image depicting a plurality of cells; applying an analytical model to each of a plurality of subsets of the image data, each subset corresponding to a respective portion of the specimen image which depicts a single cell, the analytical model configured to output, for each subset of the image data: a value parameterizing a property of the cell; and either a confidence score or an uncertainty score associated with the value, thereby generating output data comprising the plurality of confidence scores or plurality of uncertainty scores; and determining, based on the output data, whether one or more morphologically abnormal cells are likely to be present in the specimen image.

Classes IPC  ?

• G06V 10/82 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant les réseaux neuronaux
• G06V 20/69 - Objets microscopiques, p.ex. cellules biologiques ou pièces cellulaires
• G06V 10/80 - Fusion, c. à d. combinaison des données de diverses sources au niveau du capteur, du prétraitement, de l’extraction des caractéristiques ou de la classification

Abrégé

A method for predicting a maintenance condition of a filtration system of a diagnostic apparatus or a laboratory analyser at a given time is done by performing the following steps. First a plurality of successive raw permeability values of the permeability of a fluid through the filtration device over a specified measurement period is measured. Then smoothed permeability values are determined by means of a data processing method to reduce the fluctuations of the raw permeability values over time. Afterwards a regression analysis function is applied through the successive permeability values, wherein the regression analysis function comprises fitting parameters being adapted so that the fitting function is fitted to the measured permeability values. Finally, the time, when the regression analysis function will cross a predetermined threshold value is determined, wherein the crossing of the threshold value is judged as a maintenance condition.

Classes IPC  ?

• B01D 65/02 - Nettoyage ou stérilisation de membranes
• B01D 65/08 - Prévention de l'encrassement de la membrane ou de la polarisation par concentration

Abrégé

The present invention relates to diagnostic test and technology. In particular, the present invention relates to a method for determining an analyte suspected to be present in a sample comprising contacting said sample with a sensor element comprising i) an anchor layer which is present on a solid support, ii) a first binding agent which is capable of specifically binding to the analyte, which is anchored in the anchor layer and which comprises at least one detectable label, and iii) a second binding agent which is capable of specifically binding to the analyte when bound to the first binding agent and which is immobilized on the solid support, for a time and under conditions which allow for specific binding of the analyte suspected to be present in the sample to the first binding agent and specific binding of the second binding agent to the analyte bound to the first binding agent and detecting the formation of the complex of first binding agent, analyte and second binding agent whereby the analyte is determined. Moreover, provided is a device for determining an analyte suspected to be present in a sample and the use thereof for determining an analyte suspected to be present in a sample in said sample. Moreover, the present invention contemplates a kit for determining an analyte suspected to be present in a sample.

Classes IPC  ?

• G01N 33/544 - Support organique
• G01N 33/543 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques

Abrégé

The present disclosure provides the sequence of a Paenibacillus polymyxa preproenzyme which is the precursor of a neutral protease, expression thereof in a transformed host organism, and methods for production of the neutral protease, by recombinant means. Further, use of the recombinantly produced neutral protease is disclosed in the field of cell biology, particularly for the purpose of tissue dissociation. The disclosure also includes blends with other proteases. Further disclosed are nucleotide sequences encoding the neutral protease.

Classes IPC  ?

• C12N 9/52 - Protéinases provenant de bactéries
• C07K 14/195 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant de bactéries
• C12N 5/071 - Cellules ou tissus de vertébrés, p.ex. cellules humaines ou tissus humains

Abrégé

A computer implemented method for a data sharing system to share healthcare data from a healthcare data provider with a healthcare data processing application. The method includes identifying one or more healthcare data processor applications, generating and displaying selectable options of the one or more data processor applications at a healthcare data provider, obtaining a selection of the one or more data processor applications from the healthcare data provider, obtaining a data provider/application-specific encryption keyset corresponding to each selected healthcare data processor application, the keyset comprising a private key and a public key, retaining the private key of the data provider/application-specific keyset with a trusted component of the healthcare data provider, and sharing the public key of the data provider/application-specific keyset with the corresponding selected healthcare data processor application.

Classes IPC  ?

• G16H 40/20 - TIC spécialement adaptées à la gestion ou à l’administration de ressources ou d’établissements de santé; TIC spécialement adaptées à la gestion ou au fonctionnement d’équipement ou de dispositifs médicaux pour la gestion ou l’administration de ressources ou d’établissements de soins de santé, p.ex. pour la gestion du personnel hospitalier ou de salles d’opération
• G16H 10/60 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des données spécifiques de patients, p.ex. pour des dossiers électroniques de patients
• H04L 9/08 - Répartition de clés
• H04L 9/30 - Clé publique, c. à d. l'algorithme de chiffrement étant impossible à inverser par ordinateur et les clés de chiffrement des utilisateurs n'exigeant pas le secret

Abrégé

A computer-implemented method for detecting at least one analyte in a sample with a laser desorption mass spectrometer (220) is disclosed. The method comprises: a) at least one imaging step comprising imaging at least one reflective target (128) by using at least one imaging device (235), wherein the sample comprising the at least one analyte is applied to the reflective target (128); b) at least one sample recognition step comprising localizing at least one sample re- gion on the reflective target (128); and c) at least one analyte detection step comprising detecting the at least one analyte in the sample using surface assisted laser desorption ionization mass spectrometry (SALDI-MS) with the laser desorption mass spectrometer (220), wherein laser ir- radiation is applied to the reflective target (128) by using at least one laser source (222) of the laser desorption mass spectrometer (220) such that at least one ion of the at least one analyte is generated which is detected by using at least one of a mass analyzing unit (224) or an ion-mobility spectrometry device of the laser de- sorption mass spectrometer (220), wherein the laser irradiation is steered on the localized sample region by using at least one control device (237).

Classes IPC  ?

• H01J 49/00 - Spectromètres pour particules ou tubes séparateurs de particules
• H01J 49/16 - Sources d'ions; Canons à ions utilisant une ionisation de surface, p.ex. émission thermo-ionique ou photo-électrique
• H01J 49/04 - Dispositions pour introduire ou extraire les échantillons devant être analysés, p.ex. fermetures étanches au vide; Dispositions pour le réglage externe des composants électronoptiques ou ionoptiques

Abrégé

Computer-implemented methods for analysing a medical image are provided, the method comprising: obtaining a medical image; inputting the image into a machine learning model, the machine learning model trained with training medical images, by: obtaining a plurality of smaller image segments from the training medical images; obtaining an image embedding for each image segment; and processing the embeddings using one or more attention mechanisms comprising a B-cos transform. Related methods, products and systems are described.

Classes IPC  ?

• G06N 3/045 - Combinaisons de réseaux
• G06N 3/048 - Fonctions d’activation
• G06N 3/09 - Apprentissage supervisé
• G06N 3/096 - Apprentissage par transfert
• G06T 7/00 - Analyse d'image
• G06T 7/10 - Découpage; Détection de bords
• G06V 10/82 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant les réseaux neuronaux

Abrégé

An in-vitro diagnostic (IVD) analyzer (200) comprising at least one sensor (212) located in a flow-through sensor path (211) of detecting unit and requiring at least one oxygenated calibration fluid (221', 222') for calibration is herein disclosed. The IVD analyzer (200) further comprises a fluid-supply unit (220) comprising at least one deoxygenated calibration fluid (221, 222), a fluid-selection valve (230) and at least one oxygenation tubing (215, 216) having two ends connected to the fluid-selection valve (230) as a loop, wherein the oxygenation tubing (215, 216) comprises oxygen-permeable walls, and wherein the IVD analyzer (200) further comprises a pump (240) and a controller (250) configured to control the pump (240) and the fluid-selection valve (230) for transporting deoxygenated calibration fluid (221, 222) into the oxygenation tubing (215, 216), to wait a predetermined time required for oxygenation of the deoxygenated calibration fluid (221, 222) via oxygen uptake from ambient air through the tubing walls, and to transport the thereby obtained oxygenated calibration fluid (221', 222') into the sensor path (211) for calibration of the at least one sensor (212). A respective automatic method of calibrating at least one sensor (212) is herein also disclosed.

Classes IPC  ?

• C12Q 1/00 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions
• G01N 33/96 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir un étalon de contrôle du sang ou du sérum
• G01N 27/327 - Electrodes biochimiques

Produits et services

Chemical, biological and biochemical preparations for the analysis of biological samples for medical purposes; medical diagnostic assays and reagents for the analysis of biological samples for clinical or medical purposes; diagnostic reagents and preparations for medical purposes; in vitro diagnostic agents for the analysis of biological samples for medical purposes; kits consisting primarily of reagents and diagnostic preparations for clinical and medical diagnostic purposes analyzers for the analysis of biological samples for medical diagnostic purposes

Abrégé

The present invention relates to diagnostic test and technology. In particular, the present invention relates to a method for determining an analyte suspected to be present in a sample comprising contacting said sample with a sensor element comprising an anchor layer which is present on a solid support, a first binding agent which is capable of specifically binding to the analyte, which is anchored in the anchor layer and which comprises at least one magnetic label, wherein said at least one magnetic label is located within the anchor layer, a second binding agent which is capable of specifically binding to the analyte when bound to the first binding agent and which is immobilized on the solid support, and a magnetic tunnel junction in functional proximity to the second binding agent which generates a signal elicited in proximity to the at least one magnetic label of the first binding agent, for a time and under conditions which allow for specific binding of the analyte suspected to be present in the sample to the first binding agent and specific binding of the second binding agent to the analyte bound to the first binding agent and detecting the formation the complex of first binding agent, analyte and second binding agent based on the signal which is generated by the magnetic tunnel junction whereby the analyte is determined. Moreover, provided is a device for determining an analyte suspected to be present in a sample and the use thereof for determining an analyte suspected to be present in a sample in said sample. Moreover, the present invention contemplates a kit for determining an analyte suspected to be present in a sample.

Classes IPC  ?

• G01N 33/543 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques

Abrégé

The present invention relates to a method of determining an analyte in a sample by mass spectrometry (MS), the method comprising (a) admixing a pre-determined amount of internal calibrator to said sample, wherein said internal calibrator comprises at least two non-identical isotopologues of the analyte at predetermined amounts; (b) determining MS signals of ions generated from said analyte (analyte signal) and from said at least two isotopologues (isotopologue signals); (c) providing a calibration based on the analyte signal and the isotopologue signals determined in step (b); and (d) determining said analyte based on the calibration provided in step (c). Further, the present invention relates to devices, systems, and uses related thereto.

Classes IPC  ?

• G01N 33/74 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des hormones
• G01N 30/72 - Spectromètres de masse
• G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
• H01J 49/00 - Spectromètres pour particules ou tubes séparateurs de particules

Abrégé

A diagnostic device (110) for monitoring at least one body tissue (134) of a patient is disclosed. The diagnostic device (110) comprises: a. at least one bracelet (112) configured to be strapped around a body part (132) of the patient; b. at least one electromechanical actuator (114) configured for actively varying a circumference of the bracelet (112); c. at least one measurement unit (126) configured for determining at least one item of information on an electrical power applied to the electromechanical actuator (114) and at least one item of circumference information on the circumference of the bracelet (112); and d. at least one evaluation unit (128) configured for determining at least one item of information on a status of the body tissue (134) from the item of information on the electrical power applied to the electromechanical actuator (114) and the item of circumference information, wherein the evaluation unit (128) is configured for determining a point of contact at which the circumference of the bracelet (112) corresponds to the circumference of the body part. Further, a method of monitoring at least one body tissue (134) of a patient is disclosed.

Classes IPC  ?

• A61B 5/107 - Mesure de dimensions corporelles, p.ex. la taille du corps entier ou de parties de celui-ci
• A61B 5/05 - Détection, mesure ou enregistrement pour établir un diagnostic au moyen de courants électriques ou de champs magnétiques; Mesure utilisant des micro-ondes ou des ondes radio
• A61B 5/00 - Mesure servant à établir un diagnostic ; Identification des individus
• A61B 5/0205 - Evaluation simultanée de l'état cardio-vasculaire et de l'état d'autres parties du corps, p.ex. de l'état cardiaque et respiratoire

Abrégé

The present invention relates to chemical probes for the improved detection of cysteine in a test sample, preferably an aqueous test sample, as well as respective uses and kits.

Classes IPC  ?

• G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
• C07C 259/06 - Composés contenant des groupes carboxyle, un atome d'oxygène d'un groupe carboxyle étant remplacé par un atome d'azote, cet atome d'azote étant lié de plus à un atome d'oxygène et ne faisant pas partie de groupes nitro ou nitroso sans remplacement de l'autre atome d'oxygène du groupe carboxyle, p.ex. acides hydroxamiques ayant des atomes de carbone de groupes hydroxamique liés à des atomes d'hydrogène ou à des atomes de carbone acycliques

Abrégé

This automated analysis device comprises an analyzing unit 40 for analyzing a sample, and a control device 20 for controlling operations of each mechanism of the analyzing unit 40, wherein the control device 20 calculates a waiting time that a user should wait until the sample or a consumable required to analyze the sample is replaced, on the basis of a time at which the sample or the consumable is to be used last, in an analysis schedule created at a time point at which a replacement request for the sample or the consumable is accepted. By this means, the present invention provides an automated analysis device, and a method for operating the automated analysis device, capable of improving work efficiency.

Classes IPC  ?

• G01N 35/00 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes ; Manipulation de matériaux à cet effet

Abrégé

The present invention relates to reagents which are suitable to be used in mass spectrometry as well as methods of mass spectrometric determination of analyte molecules using said reagents.

Classes IPC  ?

• C07D 249/06 - Triazoles-1, 2, 3; Triazoles-1, 2, 3 hydrogénés avec des radicaux aryle liés directement aux atomes du cycle
• C07D 203/04 - Composés hétérocycliques contenant des cycles à trois chaînons ne comportant qu'un seul atome d'azote comme unique hétéro-atome du cycle  non condensés avec d'autres cycles 
• C07D 249/04 - Triazoles-1, 2, 3; Triazoles-1, 2, 3 hydrogénés
• C07D 257/04 - Cycles à cinq chaînons
• C07D 401/04 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
• C07D 401/14 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant au moins trois hétérocycles
• C07D 403/04 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
• C07D 403/06 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne carbonée ne contenant que des atomes de carbone aliphatiques
• C07D 471/04 - Systèmes condensés en ortho

Abrégé

A healthcare computer system, the computer system comprising a communications module, a string generation module, a one-way function module and an anonymised data generation module. The communications module is configured to receive one or more healthcare data packets, each healthcare data packet including: data pertaining to one or more medical analytical tests performed on a sample; a sample identifier, identifying the sample; and a timestamp, indicating when the analytical test(s) was performed. The string generation module is configured to generate a string based on the sample identifier and the timestamp. The one-way function module is configured to apply a one-way function to the generated string to generate an anonymised sample identifier. The anonymised data generation module is configured to generate an anonymised healthcare data packet including the data pertaining to the one or more medical analytical tests and the anonymised sample identifier.

Classes IPC  ?

• G16H 10/40 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des données relatives aux analyses de laboratoire, p.ex. pour des analyses d’échantillon de patient
• G06F 21/60 - Protection de données
• G16H 10/60 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des données spécifiques de patients, p.ex. pour des dossiers électroniques de patients
• H04L 9/40 - Protocoles réseaux de sécurité

Abrégé

A healthcare data management system for managing processing capacity in a healthcare data management system. The healthcare data management system includes: one or more processing pipelines connected to one or more of the medical devices and configured to receive medical data therefrom, wherein each processing pipeline comprises a plurality of processing stages arranged in series and configured to perform respective operations on the received healthcare data, wherein each processing stage is implemented on a stateless atomic processing unit; a healthcare middleware is configured to receive processed data therefrom and to provide the processed data to a healthcare information management system; a performance management unit is configured to monitor a performance of the or each processing pipeline and adjust a number of stateless atomic processing units implementing a given processing stage within a given processing pipeline based on the monitored performance.

Classes IPC  ?

• G16H 10/40 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des données relatives aux analyses de laboratoire, p.ex. pour des analyses d’échantillon de patient
• G06F 9/48 - Lancement de programmes; Commutation de programmes, p.ex. par interruption
• G16H 40/20 - TIC spécialement adaptées à la gestion ou à l’administration de ressources ou d’établissements de santé; TIC spécialement adaptées à la gestion ou au fonctionnement d’équipement ou de dispositifs médicaux pour la gestion ou l’administration de ressources ou d’établissements de soins de santé, p.ex. pour la gestion du personnel hospitalier ou de salles d’opération

Abrégé

Embodiments of the present disclosure relate to automated validation of medical data. Some embodiments of the present disclosure provide a method for medical data validation. The method comprises obtaining target medical data generated in a medical test and obtaining a machine learning model for validating medical data. The machine learning model represents an association between the medical data and validation results, the validation results indicating information about predetermined actions to be performed on the medical data. The method further comprises determining a target validation result for the target medical data by applying the target medical data to the machine learning model, the target validation result indicating information about a target action selected from the predetermined actions to be performed on the target medical data. Through the solution, it is possible to achieve automated medical data validation with high accuracy and efficiency as well as reduced manual efforts.

Classes IPC  ?

• G16H 50/70 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicales; TIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour extraire des données médicales, p.ex. pour analyser les cas antérieurs d’autres patients
• G16H 15/00 - TIC spécialement adaptées aux rapports médicaux, p.ex. leur création ou leur transmission
• G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicales; TIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p.ex. basé sur des systèmes experts médicaux

Abrégé

A monitoring device for monitoring a sample handling system comprising: a sliding unit comprising a sliding surface, wherein the sliding unit is configured for sliding over a sample transport device of the sample handling system; and an imaging streaming unit comprising s camera, wherein the camera is configured for capturing a plurality of images, wherein the imaging streaming unit comprises an imaging communication interface for providing the plurality of captured images to a transport control system of the sample handling system. A monitoring device for monitoring a sample handling system comprising: a sliding unit comprising a sliding surface, wherein the sliding unit is configured for sliding over a sample transport device of the sample handling system; and an imaging streaming unit comprising s camera, wherein the camera is configured for capturing a plurality of images, wherein the imaging streaming unit comprises an imaging communication interface for providing the plurality of captured images to a transport control system of the sample handling system. Further disclosed is a transport control system for controlling transport of a plurality of sample container holders of a sample handling system, a sample handling system for handling a plurality of samples, a method for identifying an obstacle, a method for determining a distance between the obstacle and a monitoring device and a method for controlling a monitoring device and computer programs and computer-readable storage media for performing the methods.

Classes IPC  ?

• G01N 35/00 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes ; Manipulation de matériaux à cet effet
• G01N 35/02 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes ; Manipulation de matériaux à cet effet en utilisant une série de récipients à échantillons déplacés par un transporteur passant devant un ou plusieurs postes de traitement ou d'analyse
• G06T 7/55 - Récupération de la profondeur ou de la forme à partir de plusieurs images
• G06V 10/82 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant les réseaux neuronaux
• G06V 20/64 - Objets tridimensionnels

Abrégé

Fusion polypeptides are disclosed which are substrates for Kutzneria albida transglutaminase. The fusion polypeptides comprise one or more FKBP chaperone(s) and a target polypeptide. Each of these elements is separated from the neighboring element by a linker amino acid sequence. It was found that inserting glutamic acid containing transglutaminase recognition motifs into the linker amino acid chains is advantageous. Subsequent labeling reactions catalyzed by the transglutaminase surprisingly provide labeled fusion polypeptides have superior properties when compared with chemically random-labeled fusion polypeptides of similar design. Assays and kits are provided for in vitro detection of target antibodies in samples.

Classes IPC  ?

• C07K 14/435 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains
• C07K 14/005 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant de virus
• G01N 33/569 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour micro-organismes, p.ex. protozoaires, bactéries, virus
• G01N 33/58 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des substances marquées

Abrégé

The disclosure concerns methods for the detection of an analyte in a sample by electro-chemiluminescence using new reagent compositions. New reagent compositions, reagent kits for measuring electrochemiluminscence (ECL) and electrochemiluminescence detection methods using the new reagent compositions are disclosed. In particular, the disclosure relates to the use of novel combinations of compounds which can be used in said measurements to provide improved assay performance.

Classes IPC  ?

• G01N 21/76 - Chimioluminescence; Bioluminescence
• G01N 33/543 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
• C07F 15/00 - Composés contenant des éléments des groupes 8, 9, 10 ou 18 de la classification périodique
• G01N 21/66 - Systèmes dans lesquels le matériau analysé est excité de façon à ce qu'il émette de la lumière ou qu'il produise un changement de la longueur d'onde de la lumière incidente excité électriquement, p.ex. par électroluminescence

Abrégé

A method for automatically closing an open end of a sample vessel with a closure cap, including, inter alia, the steps of grasping an upper part of the closure cap at its outer circumference by means of a cap gripper with at least two gripper fingers comprising respective top thrust ledges extending at least in part over a recess provided by a lateral gripping face, and of pushing the closure cap into the open end of the sample vessel by means of the top thrust ledge. In addition, a respective movable cap gripper for automatically closing the open end of the sample vessel with the closure cap as well as a respective sample vessel closure system is provided.

Classes IPC  ?

• B65B 7/28 - Fermeture de réceptacles ou récipients semi-rigides ou rigides, non déformés par le contenu ou n'en prenant pas la forme, p.ex. boîtes ou cartons en appliquant des fermetures séparées préformées, p.ex. couvercles, capuchons
• G01N 35/00 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes ; Manipulation de matériaux à cet effet

Abrégé

The present invention relates to a method for assessing whether a subject has Polycystic Ovarian Syndrome (PCOS) or is at risk of developing PCOS, to a method of selecting a patient for therapy of PCOS, to a method for monitoring PCOS progression or for monitoring response to treatment and to a computer-implemented method for assessing a subject with suspected PCOS, by determining the amount or concentration of Leukotriene A4 Hydrolase (LTA4H) in a sample of the subject.

Classes IPC  ?

• G01N 33/88 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des prostaglandines

Abrégé

The present invention relates to a method for assessing whether a subject has Polycystic Ovarian Syndrome (PCOS) or is at risk of developing PCOS, to a method of selecting a patient for therapy of PCOS, to a method for monitoring PCOS progression or for monitoring response to treatment and to a computer- implemented method for assessing a subject with suspected PCOS, by determining the amount or concentration of Meteorin-like protein (METRNL) in a sample of the subject.

Classes IPC  ?

• G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

The present invention relates to a method for assessing whether a subject has Polycystic Ovarian Syndrome (PCOS) or is at risk of developing PCOS, to a method of selecting a patient for therapy of PCOS, to a method for monitoring PCOS progression or for monitoring response to treatment and to a computer- implemented method for assessing a subject with suspected PCOS, by determining the amount or concentration of Fibroblast Growth Factor-Binding Protein 1 (FGFBP1) in a sample of the subject.

Classes IPC  ?

• G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

A computer-implemented method of automatically locating and processing test sample(s) from a patient within a laboratory setting 100 is disclosed. The method comprises determining that a test sample has not been processed by any device in the laboratory and the test sample is still within a time period of processing, performing inquiry of historical data of previous non-located test samples maintained in a database for possible locations of non-located test sample, and notifying laboratory operator of a location with a highest probability of test sample location based on the historical data.

Classes IPC  ?

• G16H 10/40 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des données relatives aux analyses de laboratoire, p.ex. pour des analyses d’échantillon de patient

Abrégé

A computer-implemented method of consolidating critical information for a patient in a laboratory is presented. The method comprises selecting a patient to monitor from a population of patients associated with the laboratory, extracting information for the patient from a plurality of laboratory sources in the laboratory, determining if the extracted patient information is critical to care of the patient, and outputting the extracted patient critical information to a single display dashboard for display to a laboratory operator.

Classes IPC  ?

• G16H 10/40 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des données relatives aux analyses de laboratoire, p.ex. pour des analyses d’échantillon de patient
• G16H 15/00 - TIC spécialement adaptées aux rapports médicaux, p.ex. leur création ou leur transmission
• G16H 40/20 - TIC spécialement adaptées à la gestion ou à l’administration de ressources ou d’établissements de santé; TIC spécialement adaptées à la gestion ou au fonctionnement d’équipement ou de dispositifs médicaux pour la gestion ou l’administration de ressources ou d’établissements de soins de santé, p.ex. pour la gestion du personnel hospitalier ou de salles d’opération

Abrégé

The present invention relates to methods of assessing whether a patient has endometriosis or is at risk of developing endometriosis and in particular early stages to methods of selecting a patient for therapy and to methods for monitoring disease progression in a patient suffering from endometriosis or being treated for endometriosis by determining the amount or concentration of PSP94 in a sample of the patient, and comparing the determined amount or concentration to a reference.

Classes IPC  ?

• G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

The present invention relates to a method for diagnosing Polycystic Ovarian Syndrome (PCOS) in a subject, said method comprising the steps of a) determining the amount or concentration of total LTA4H in sample from the subject, b) determining the amount or concentration of METRNL in a sample from the subject, c) calculating a score of the amounts or concentration determined in steps a) and b), d) comparing the calculated score with a reference score, and e) diagnosing PCOS in a subject.

Classes IPC  ?

• G01N 33/88 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des prostaglandines

Abrégé

The present invention relates to a method for diagnosing Polycystic Ovarian Syndrome (PCOS) in a subject, said method comprising the steps of a) determining the amount or concentration of total FGFBP1 in sample from the subject, b) determining the amount or concentration of METRNL in a sample from the subject, c) calculating a score of the amounts or concentrations determined in steps a) and b), d) comparing the calculated score with a reference score, and e) diagnosing PCOS in a subject.

Classes IPC  ?

• G01N 33/563 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet faisant intervenir des fragments d'anticorps
• G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

A laboratory apparatus for use in a laboratory sample handling system, wherein the apparatus comprises a cap waste disposal catcher, wherein the catcher is designed to catch a laboratory cap removed from a laboratory sample container containing a laboratory sample, and an electric field generator, wherein the generator is designed to generate an electric field to attract a residue of the sample released by the cap to the catcher.

Classes IPC  ?

• G01N 35/02 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes ; Manipulation de matériaux à cet effet en utilisant une série de récipients à échantillons déplacés par un transporteur passant devant un ou plusieurs postes de traitement ou d'analyse
• G01N 35/04 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes ; Manipulation de matériaux à cet effet en utilisant une série de récipients à échantillons déplacés par un transporteur passant devant un ou plusieurs postes de traitement ou d'analyse - Détails du transporteur
• B01L 9/06 - Supports de tubes à essai; Porte-tubes à essai

Abrégé

The disclosure refers to a method of operating a laboratory sample distribution system having a plurality of carriers (4) configured to carry one or more sample containers containing a sample to be analyzed by laboratory devices (3); a transport plane (1) assigned to the laboratory devices (3) and providing support to the plurality of carriers (4); and a driving device (13) configured to move, in response to driving control signals, the plurality of carriers (4) between plane positions (5) provided on the transport plane (1). The method comprises: prior to moving the carriers (4) on the transport plane (1), pre-determining off-line routes (6) on the transport plane (1) by one or more processors of a data processing device, the pre-determining comprising: determining a model representing the transport plane (1) with plane locations (5') and location-to-location movements between plane locations (5') associated to the plurality of carriers (4) calculating an optimized set of off-line routes between pairs of plane locations from the plurality of plane locations (5') using the model, the calculating comprising solving an optimization problem in which routes between the pairs of plane locations are simultaneously optimized; and providing the optimized set of off-line routes as off-line routes (6) on the transport plane (1); and controlling the driving device (13) such that the carriers (4) are moved along the pre-determined off-line routes (6) on the transport plane (1). Furthermore, a laboratory sample distribution system, and a laboratory automation system are provided.

Classes IPC  ?

• G06Q 10/0835 - Relations entre l’expéditeur ou le fournisseur et les transporteurs
• B65G 54/02 - Transporteurs non mécaniques, non prévus ailleurs électrostatiques, électriques ou magnétiques
• G01N 35/04 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes ; Manipulation de matériaux à cet effet en utilisant une série de récipients à échantillons déplacés par un transporteur passant devant un ou plusieurs postes de traitement ou d'analyse - Détails du transporteur

Abrégé

The disclosure refers to a method of operating a laboratory sample distribution system having: a plurality of carriers (4) having a number of n (n>3) carriers (4) each configured to carry one or more sample containers containing a sample to be analyzed by laboratory devices (3); a transport plane (1) configured to support to the plurality of carriers (4), wherein the transport plane (1) comprises a plurality of interconnected transport modules comprising a plurality of plane fields (5); and a driving device (13) configured to control movement of the plurality of carriers (4) along individual routes between the plurality of plane fields (5). The method com- prises: moving the plurality of carriers (4) along the individual routes on the transport plane (1), wherein the moving, for each carrier, comprises executing at least once steps of reserving a route segment along the individual route, the route segment being provided by one or more plane fields of the plurality of plane fields (5), and moving the carrier (4) along the route seg- ment; and preventing, for the plurality of carriers (4), a deadlock arrangement on the transport plane in which the plurality of carriers (4) block each other from further movement along the individual routes (6). The preventing is further comprising: determining, at a present operation time, a potential deadlock arrangement for the plurality of carriers (4) on the transport plane (1) at a future operation time, wherein the potential deadlock arrangement is assigned a number of n deadlock plane fields occupied by the plurality of carriers (4) in case of the potential dead- lock arrangement; for a first carrier from the plurality of carriers (4) moving along a first individ- ual route, reserving a first route segment ending with a first end plane field; and assigning a non-reserve flag to a next plane field which is next to the first end plane field along the first individual route. Further, a laboratory sample distribution system, and a laboratory automation system are provided.

Classes IPC  ?

• G01N 35/04 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes ; Manipulation de matériaux à cet effet en utilisant une série de récipients à échantillons déplacés par un transporteur passant devant un ou plusieurs postes de traitement ou d'analyse - Détails du transporteur
• G06Q 10/0835 - Relations entre l’expéditeur ou le fournisseur et les transporteurs
• B65G 54/02 - Transporteurs non mécaniques, non prévus ailleurs électrostatiques, électriques ou magnétiques

Abrégé

A method for quality check of at least one Liquid Chromatography-Mass Spectrometry (LC-MS) measurement on a sample comprising an analyte of interest and a defined amount of at least one internal standard is proposed. The method comprises the following steps a) (120) determining an information (peakAreaaqn) about an analyte signal and an information (peakAreatqn) about an internal standard signal of the LC-MS measurement; b) (122) determining at least one monitoring parameter by using the information about the analyte signal and the information about the internal standard signal by using at least one processing device (114), wherein the monitoring parameter comprises a minimal limit for the internal standard signal for said analyte signal of said sample; c) (124) comparing the information about the internal standard signal to the monitoring parameter by using the processing device (114), wherein the LC-MS measurement is flagged by using the processing device (114) as to fulfil the quality check in case the information about the internal standard signal is greater or equal to the monitoring parameter or otherwise as failed.

Classes IPC  ?

• G01N 30/04 - Préparation ou injection de l'échantillon à analyser
• G01N 30/86 - Analyse des signaux

Abrégé

A door mechanism device (110) for a door (100) for a transport apparatus (500) for trans- porting a sample container carrier is disclosed. The door mechanism device (110) comprises at least a first fixation bracket (112) configured for mounting the door mechanism device (110) to a frame of the transport apparatus, at least a first upper lever (114), at least a first lower lever (116), at least a first door mount (120) configured to be mounted to a cover (102) of a door (100) of the transport apparatus. The first upper lever (114) and the first lower lever (116) are rotatably mounted to the first fixation bracket (112) and the first door mount (120). The first upper lever (114) and the first lower lever (116) are rotatable around lever axes (122) such that the first door mount (120) is movable between a first position and a second position with the first door mount (120) substantially maintaining its orientation within a plane perpendicular to the lever axes (122). Further, a door (100) for a transport apparatus for transporting a sample container carrier and a transport apparatus (500) for transporting a sample container carrier are disclosed.

Classes IPC  ?

• E05D 15/40 - Suspensions pour battants portés par des bras mobiles dans des plans verticaux
• E05D 15/46 - Suspensions pour battants portés par des bras mobiles dans des plans verticaux à deux couples de bras pivotants
• E05F 5/00 - Dispositifs de freinage, p.ex. ralentisseurs; Butées; Tampons
• G01N 35/00 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes ; Manipulation de matériaux à cet effet

Abrégé

The present disclosure relates to a computer implemented method of managing sample processing priorities in a diagnostic laboratory comprising at least one sample processing device connected to a host system. The method comprises generating a communication message between the host system and the at least one sample processing device related to a sample processing order received in association with a sample, the message comprising one of at least two priority identifiers (R, S) indicative of respective sample processing priorities from lower priority to higher priority according to the received sample processing order. The method further comprises identifying the sample by the at least one sample processing device and processing the sample by the at least one sample processing device according to the sample processing priority (S, R) in the message. In case of receiving a subsequent request for change of sample processing priority for the sample from a lower priority to a higher priority after transmission of the message and before the sample is processed, the method comprises changing the message and processing the sample as a higher priority sample instead of as a lower priority sample, wherein changing the message comprises changing the lower priority identifier (R) to an identifier (CS) indicative of a change of priority but different from an equivalent higher priority identifier (S) in order to maintain the sample and the sample processing order uniquely identifiable and traceable by both the host system and the at least one sample processing device. A respective system for managing sample processing priorities is herein also disclosed.

Classes IPC  ?

• G16H 10/40 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des données relatives aux analyses de laboratoire, p.ex. pour des analyses d’échantillon de patient
• G06F 9/48 - Lancement de programmes; Commutation de programmes, p.ex. par interruption
• G06F 9/54 - Communication interprogramme

Abrégé

A method of operating a distribution system (110), wherein the distribution system (110) comprises - a number of carriers (112) configured for carrying one or more objects (114), - a transport plane (122) configured for supporting the carriers (112), wherein the transport plane (122) comprises a plurality of transport modules (124), wherein a grid (126) of logical positions (128) is defined on the transport plane (122), - a drive system (130) configured for moving the carriers (112) on the transport plane (122) between the logical positions (128), - a control system (136) configured for controlling the drive system (130), wherein the control system (136) comprises a routing system (138) configured for calculating routes for the carriers (112), wherein the method comprises the steps: a) defining a global pattern of safe points (148) and applying the global pattern on the transport plane (122) by using the routing system (138), wherein safe points (148) are logical positions (128) selected in view of a range of motion for a carrier (112) occupying said logical position (128) such that on the safe points (148) a carrier (112) can be placed and can be moved away again, wherein the global pattern is applied onto the transport plane (122) independently of module boundaries; b) calculating partial routes for the carriers (112) so that an end position of each partial route is either one of the safe points (148) or has a free path to one of the safe points (148) to be reachable in the next partial route by using the routing system (138). Further, a distribution system (110) and a computer program and a computer-readable storage medium for performing the method according to the present invention are disclosed.

Classes IPC  ?

• G01N 15/04 - Recherche de la sédimentation des suspensions de particules
• B65G 35/06 - Transporteurs mécaniques non prévus ailleurs comportant un porte-charges se déplaçant le long d'un circuit, p.ex. d'un circuit fermé, et adapté pour venir en prise avec l'un quelconque des éléments de traction espacés le long du circuit
• G01N 35/00 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes ; Manipulation de matériaux à cet effet
• G06Q 10/04 - Prévision ou optimisation spécialement adaptées à des fins administratives ou de gestion, p. ex. programmation linéaire ou "problème d’optimisation des stocks"
• G06Q 10/08 - Logistique, p.ex. entreposage, chargement ou distribution; Gestion d’inventaires ou de stocks
• G01N 35/04 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes ; Manipulation de matériaux à cet effet en utilisant une série de récipients à échantillons déplacés par un transporteur passant devant un ou plusieurs postes de traitement ou d'analyse - Détails du transporteur

Abrégé

A distribution system (110) and a method for distributing a plurality of carriers (114) using the distribution system (110) are disclosed. The distribution system (110) comprises: - at least one transport plane (118) comprising logical positions (120); - a plurality of carriers (114) for transporting objects (122); - at least one drive system (126) for moving the carriers (114) on the transport plane (118) between the logical positions (120); and - at least one control system (128) configured for controlling the carriers (114) to move on a planned route from a start position to a final destination position on the transport plane (118), wherein the planned route comprises partial routes (144), wherein the control system (128) comprises at least one routing system (130) configured for calculating routing plans for carriers (114) on the transport plane (118) by modeling the transport plane (118) with graph of nodes (132), wherein the routing system (130) is configured for calculating the routing plans considering moving time periods (160) and waiting time periods (162), wherein the routing system (130) is configured for assigning waiting time periods (162) for carriers (114) depending on a reservation of logical positions (120) of the partial routes (144) of other carriers (114), wherein, if a carrier (114) experiences a time delay (158) during execution of a move, the routing system (130) is configured for shifting the experienced time delay (158) to at least one upcoming waiting time period (166) of a carrier (114).

Classes IPC  ?

• G01N 35/00 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes ; Manipulation de matériaux à cet effet
• G01N 35/04 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes ; Manipulation de matériaux à cet effet en utilisant une série de récipients à échantillons déplacés par un transporteur passant devant un ou plusieurs postes de traitement ou d'analyse - Détails du transporteur
• B65G 35/06 - Transporteurs mécaniques non prévus ailleurs comportant un porte-charges se déplaçant le long d'un circuit, p.ex. d'un circuit fermé, et adapté pour venir en prise avec l'un quelconque des éléments de traction espacés le long du circuit
• G06Q 10/04 - Prévision ou optimisation spécialement adaptées à des fins administratives ou de gestion, p. ex. programmation linéaire ou "problème d’optimisation des stocks"
• G06Q 10/08 - Logistique, p.ex. entreposage, chargement ou distribution; Gestion d’inventaires ou de stocks

Abrégé

The present invention relates to methods of diagnosing whether a subject has endometriosis, to methods of classifying the stage of endometriosis, to methods of determining the therapeutic effect of a treatment regimen for endometriosis, and methods of monitoring endometriosis progression in a subject, by determining the amount or concentration of c-Kit in a sample of the subject, and comparing the determined level to a reference value.

Classes IPC  ?

• G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

The present invention relates to a clinical diagnostic system, a method for determining the presence or level of at least one analyte of interest in a biological sample, a kit and the uses thereof for efficiently and/or robust detection of an analyte of interest.

Classes IPC  ?

• H01J 49/26 - Spectromètres de masse ou tubes séparateurs de masse
• G01N 1/40 - Concentration des échantillons

Abrégé

The present invention relates to monoclonal antibodies binding to the nucleocapsid protein of SARS-CoV-2 virus, nucleic acids encoding said antibody, host cells producing the same, compositions and kits comprising said antibodies, as well as methods of detecting SARS-CoV-2 virus in a sample comprising using said antibodies.

Classes IPC  ?

• C07K 16/10 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN

Abrégé

A method for multiple reaction monitoring using a mass spectrometry device (106) is proposed. The method comprises the following steps: i) (128) measuring, by using the mass spectrometry device (106), multiple reaction monitoring transitions of quantifier and qualifier of both an internal standard and an analyte using staggered- multiple reaction monitoring, wherein the staggered-multiple reaction monitoring comprises at least three multiple reaction monitoring channel groups, wherein one of the multiple reaction monitoring channel groups measure at respective theoretical m/z values of the quantifier and qualifier of both the internal standard and the analyte and the two other multiple reaction monitoring channel groups measure at respective m/z values shifted to higher and lower values by a predefined level; ii) (130) comparing, for at least two groups, at least two of the quantifier/qualifier ratios of the multiple reaction monitoring transitions of the internal standard with a reference value from a database (126) by using at least one processing device (120), wherein the comparison comprises determining a deviation between the quantifier/qualifier ratios and the reference value; iii) (132) determining from the analyte and the internal standard measured multiple reaction monitoring transitions a measurement result by using the processing device (120), if the deviation for at least one of the quantifier/qualifier ratios is within at least one predefined tolerance range, otherwise rejecting (136) the measured multiple reaction monitoring transitions.

Classes IPC  ?

• H01J 49/00 - Spectromètres pour particules ou tubes séparateurs de particules

Abrégé

A method for determining system resistance of at least one power supply of a handheld medical device, the method including: a) generating at least one excitation voltage signal, wherein the excitation voltage signal comprises at least one direct current (DC) voltage signal, wherein the excitation voltage signal has a fast transition DC flank of 20 ns or less; b) applying the excitation voltage signal to at least one reference resistor having a predetermined or pre-defined resistance value, wherein the reference resistor is arranged in series with the power supply; c) measuring a response signal of the power supply; d) determining a signal flank from the response signal and determining an ohmic signal portion from one or both of shape and height of the signal flank; and e) determining the system resistance of the power supply from the ohmic signal portion.

Classes IPC  ?

• G01R 27/14 - Mesure d'une résistance par mesure d'un courant ou d'une tension issus d'une source de référence
• G01R 31/36 - Dispositions pour le test, la mesure ou la surveillance de l’état électrique d’accumulateurs ou de batteries, p.ex. de la capacité ou de l’état de charge

Abrégé

A computer-implemented method, system and decision support system adapted to provide arterial venous blood gas values without the provision of an arterial oxygenation saturation value or arterial blood gas values. The method comprises the provision of arterial blood gas values from a subject, for which said subject, only venous blood gas values are provided, by providing a mathematical model adapted to convert said venous blood gas values with a provided predefined default arterial oxygenation value to output arterial blood gas values of said subject. The present invention thus provides a method for providing arterial blood gas values from a specific subject without the need of providing an arterial blood sample from a painful arterial blood draw or the need for an arterial oxygenation saturation value of the subject, thus reducing distress to said patient and a reduction of tasks to relevant health care personnel.

Classes IPC  ?

• A61B 5/145 - Mesure des caractéristiques du sang in vivo, p.ex. de la concentration des gaz dans le sang, de la valeur du pH du sang
• A61B 5/00 - Mesure servant à établir un diagnostic ; Identification des individus
• G16H 50/50 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicales; TIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour la simulation ou la modélisation des troubles médicaux
• G01N 33/49 - Analyse physique de matériau biologique de matériau biologique liquide de sang

Abrégé

The present invention concerns the field of re-usable immunosensors. In particular, it relates to a method for regenerating an immunosensor comprising at least one polypeptide attached to an electroconductive surface of said immunosensor, wherein the at least one polypeptide is capable of specifically binding an analyte to be detected by the immunosensor, said method comprising the step of applying to the immunosensor at a temperature selected from the temperature range from about 35°C to about 42°C a positive electrical potential of about 0.3 V on said electroconductive surface of the immunosensor for a time sufficient to allow regeneration. Moreover, it also relates to a regenerated immunosensor obtainable by the method of the present invention and a system and device comprising the immunosensor as described herein, wherein said device is capable of applying a positive electrical potential of about 0.3 V on said electro conductive surface of the immunosensor for a time sufficient to allow regeneration. The present invention also contemplates, in general, the use of a temperature selected from the temperature range from about 35°C to about 42°C and a positive electrical potential of about 0.3 V on an electro conductive surface of an immunosensor as described in any one of claims 1 to 13 for regeneration of said immunosensor.

Classes IPC  ?

• G01N 33/543 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques

Abrégé

The disclosure relates to a sample container holding and/or transporting device having an aperture with a longitudinal axis, which aperture is configured for receiving a sample container, wherein a biasing structure is provided in the aperture, which comprises a plurality of elastically deflectable nubs, wherein the nubs are distributed spatially discrete along the longitudinal axis of the aperture. The disclosure further relates to a use of a structure having nubs as a biasing structure in a sample container holding and/or transporting device, and to a laboratory automation system comprising a sample container holding and/or transporting device.

Classes IPC  ?

• B01L 9/06 - Supports de tubes à essai; Porte-tubes à essai

Abrégé

The present disclosure relates to a method of preparing a magnetic particle having a polymer matrix (P) and at least one magnetic core (M), preferably at least two magnetic cores (M), wherein the polymer matrix (P) comprises at least one hypercrosslinked polymer, wherein the method comprises (i) providing at least one magnetic core (M), preferably at least two magnetic cores (M), (ii) providing polymer precursor molecules, (iii) polymerizing the polymer precursor molecules according to (ii) in the presence of the at least one magnetic core (M), thereby forming a particle comprising the at least one magnetic core (M). Further, the present disclosure relates to particles obtained or obtainable by this method as well as to the use of these particles. In a further aspect, the disclosure relates to a method for determining at least one analyte in a fluid sample having the step of contacting of the magnetic particle with a fluid sample having or suspected of having the at least one analyte.

Classes IPC  ?

• B01J 20/28 - Compositions absorbantes ou adsorbantes solides ou compositions facilitant la filtration; Absorbants ou adsorbants pour la chromatographie; Procédés pour leur préparation, régénération ou réactivation caractérisées par leur forme ou leurs propriétés physiques
• B01J 20/26 - Composés macromoléculaires synthétiques
• B01J 20/32 - Imprégnation ou revêtement
• B03C 1/01 - Prétraitement spécialement adapté à la séparation magnétique par addition d'agents magnétiques
• G01N 33/543 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques

Abrégé

The present invention relates to bacterial pilus protein complex FimGt-DsF stabilized protein complexes for producing phagemids or filamentous phages, and methods for use of these.

Classes IPC  ?

• C07K 14/245 - Escherichia (G)
• C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN

Abrégé

A column device for an automatic analyser. The automatic analyzer comprises a high performance liquid chromatography (HPLC) module. The HPLC module comprises a fixation device configured to automatically fix and release a chromatographic column. The column device comprises a column jacket and a capillary. The capillary comprises predetermined dimensions and is disposed within the column jacket. The column device is configured to be installed at the HPLC module using the fixation device. Further, an automatic analyzer is disclosed.

Classes IPC  ?

• G01N 30/16 - Injection
• G01N 30/60 - Préparation de la colonne
• G01N 35/00 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes ; Manipulation de matériaux à cet effet

Abrégé

A gripping apparatus for gripping a sample container comprising: a gripper body comprising a gripper actuator; at least two gripper fingers each comprising a gripping surface, wherein at least one of the gripper fingers is movably coupled to the gripper body, and wherein the gripping apparatus is designed for gripping a sample container with the gripping surfaces of the at least two gripper fingers by moving the at least one movable gripper finger; and characterized in that the gripping apparatus comprises at least one elastically mounted contacting surface for elastically contacting a sample container about to be gripped by the gripping apparatus.

Classes IPC  ?

• B25J 15/08 - Têtes de préhension avec des éléments en forme de doigts
• B25J 15/00 - Têtes de préhension

Abrégé

The present invention relates to monoclonal antibodies and antigen binding fragments that specifically bind to α-1,6-core-fucosylated alpha-fetoprotein (AFP), which is the core component of AFP-L3. Thus, the antibodies and antigen binding fragments provided herein may also be referred to as AFP-L3 antibodies. Also provided are polynucleotides encoding the antibodies or antigen binding fragments of the invention, host cells expressing the antibodies and antigen binding fragments of the invention, methods for producing the antibodies and antigen binding fragments of the invention, and uses of the antibodies and antigen binding fragments of the invention. Also provided herein is a pretreatment agent facilitating the binding of the antibodies and antigen binding fragments of the invention to α-1,6-core-fucosylated AFP. The present invention further relates to kits comprising the antibodies and antigen binding fragments of the invention and optionally the pretreatment agent of the invention.

Classes IPC  ?

• C07K 16/18 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
• G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique

Abrégé

The present disclosure refers to a method for operating a sorter device (5) in an IVD laboratory system, the method comprising providing a sorter device (5) in an IVD laboratory system (1) provided with a system operation controller (3), the sorter device (5) having a plurality of sample container racks each provided with reception holes for receiving sample containers (4), a handling device configured to pick sample containers (4) from and place sample containers (4) in the reception holes of the sample container racks, a sorter device controller configured to control operation of the sorter device (5) and connectable to the system operation controller (3), and an output device functionally connected to the sorter device controller and configured to output at least one of audio data and video data. The sorter device (5) is configured in a pre-operation process, the configuring comprising: assigning the plurality of sample container racks to a plurality of processing sub-targets conducted by the IVD laboratory system (1) in operation, wherein a first sample container rack is assigned to a first processing sub-target and a second sample container rack is assigned to a second processing sub-target which is different from the first processing sub- target, and assigning to the first sample container rack a first threshold value indicative of a first threshold number of sample containers (4) in the first sample container rack, wherein the first threshold number of sample containers (4) is smaller than a maximum number of sample containers (4) receivable in the first sample container rack. The sorter device (5) is operated in an operation process, the operating comprising: placing sample containers (4) in the reception holes of the first sample container rack by the handling device, determining a first present number of sample containers (4) received in the first sample container rack by the sorter device controller, comparing the first present number of sample containers (4) to the first threshold value by the sorter device controller, and if the first present number of sample containers (4) is equal to or greater than the first threshold value, outputting a first warning data through the output device. Furthermore, an IVD laboratory system (1) is provided.

Classes IPC  ?

• G01N 35/00 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes ; Manipulation de matériaux à cet effet

Abrégé

The present invention relates to a method for diagnosing atrial fibrillation in a subject, said method comprising the steps of a) determining the amount of total NT-proBNP in sample from the subject, b) determining the amount of unglycosylated NT-proBNP in a sample from the subject, c) calculating a score of the amounts determined in steps a) and b), d) comparing the calculated score with a reference score, and e) diagnosing atrial fibrillation in a subject.

Classes IPC  ?

• G01N 33/74 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des hormones

Abrégé

The present disclosure relates to a laboratory data management system 100 comprising a data source layer 10 comprising at least one laboratory device 11, 12, 13, 14, 15 as a data source, a data adapter layer 20 comprising at least one data source agent 21, 22, 23, 24, 25 configured to obtain data from the at least one data source and to convert the data from a data source format to a data-source independent format, a consumer layer 30 configured for installation and/or execution of consumer application software 31, 32, 33, 34, and a data management layer 40 between the data adapter layer 20 and the consumer layer 30. The data management layer 40 comprises a data storage 50 configured to store data 1-n converted by the at least one data source agent 21, 22, 23, 24, 25, at least one data manager 41, 42, 43, 44 programmed to execute instructions from the consumer application software 31, 32, 33, 34, which when executed cause the at least one data manager 41, 42, 43, 44 to select application-specific data in the data storage 50 and to make them accessible to a consumer via the consumer application software 31, 32, 33, 34 in a consumer format. The data adapter layer 20 and the data management layer 40 are arranged in a laboratory gateway 60 connected to the data-source layer 10 and to the consumer layer 30.

Classes IPC  ?

• G16H 10/40 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des données relatives aux analyses de laboratoire, p.ex. pour des analyses d’échantillon de patient
• G16H 40/40 - TIC spécialement adaptées à la gestion ou à l’administration de ressources ou d’établissements de santé; TIC spécialement adaptées à la gestion ou au fonctionnement d’équipement ou de dispositifs médicaux pour la gestion d’équipement ou de dispositifs médicaux, p.ex. pour planifier la maintenance ou les mises à jour

Abrégé

samplecalibration,avsamplecalibration,avcalibration,av by using the processing device (130).

Classes IPC  ?

• G01N 35/00 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes ; Manipulation de matériaux à cet effet
• G01N 30/06 - Préparation
• G01N 35/10 - Dispositifs pour transférer les échantillons vers, dans ou à partir de l'appareil d'analyse, p.ex. dispositifs d'aspiration, dispositifs d'injection
• G01N 1/38 - Dilution, dispersion ou mélange des échantillons
• G01N 30/72 - Spectromètres de masse

Abrégé

The present invention relates to a method for determining a lactone analyte in a sample, comprising (i) contacting said sample with a derivatization reagent comprising a nucleophilic reagent; (ii) determining a nucleophilic reagent-derivative of said lactone analyte obtained in step (i), and (iii) determining said lactone analyte based on the determination of the nucleophilic reagent-derivative of said lactone analyte in step (ii). The present invention also relates to methods uses, compounds, kits and devices related thereto.

Classes IPC  ?

• G01N 33/94 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des narcotiques

Abrégé

ƒpp cƒpp PP ≥ 1. In each adjustment step a signal adjustment function or a concentration adjustment function is determined and at least one target concentration value is assigned.

Classes IPC  ?

• G16H 10/40 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des données relatives aux analyses de laboratoire, p.ex. pour des analyses d’échantillon de patient
• G01N 33/00 - Recherche ou analyse des matériaux par des méthodes spécifiques non couvertes par les groupes
• G01N 35/00 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes ; Manipulation de matériaux à cet effet

Abrégé

The present invention relates to an in vitro method for assessing the risk of non-small cell lung carcinoma (NSCLC) disease progression for a subject classified to have stable disease under an ongoing NSCLC treatment regime. The method involves determining the level of CYFRA 21-1 and/or the level of CA 125 in a sample obtained from the subject; and comparing (i) the determined level of CYFRA 21-1 to a CYFRA 21-1 cut-off level, (ii) the determined level of CA 125 to a CA 125 cut-off level, or (iii) a score taking into account the determined level of CYFRA 21-1 and/or the determined level of CA 125 to a cut-off score. The method of the invention further allows for assessing whether the subject responds to the ongoing treatment and/or whether the treatment regime should be maintained or modified. The invention also provides for corresponding uses, computer-implemented methods and computer program products.

Classes IPC  ?

• G01N 33/574 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour le cancer

Abrégé

A method for processing data of an analytical instrument for analyzing biological samples is presented. The method comprises receiving instrument data from the analytical instrument at a data processing module communicatively connected with the analytical instrument, generating metadata from the received instrument data at the data processing module, applying a first encryption to the instrument data at the data processing module, applying a second encryption to the generated metadata at the data processing module, and transmitting the encrypted metadata and encrypted instrument data to a remote server. The remote server and the data processing module are communicatively connected. The method also comprises removing the second encryption from the metadata at the remote server and forwarding the instrument data encrypted by the first encryption from the remote server to a management system of the analytical instrument.

Classes IPC  ?

• H04L 9/40 - Protocoles réseaux de sécurité
• G16H 10/60 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des données spécifiques de patients, p.ex. pour des dossiers électroniques de patients
• G16H 40/67 - TIC spécialement adaptées à la gestion ou à l’administration de ressources ou d’établissements de santé; TIC spécialement adaptées à la gestion ou au fonctionnement d’équipement ou de dispositifs médicaux pour le fonctionnement d’équipement ou de dispositifs médicaux pour le fonctionnement à distance
• A61B 5/00 - Mesure servant à établir un diagnostic ; Identification des individus
• G16H 40/20 - TIC spécialement adaptées à la gestion ou à l’administration de ressources ou d’établissements de santé; TIC spécialement adaptées à la gestion ou au fonctionnement d’équipement ou de dispositifs médicaux pour la gestion ou l’administration de ressources ou d’établissements de soins de santé, p.ex. pour la gestion du personnel hospitalier ou de salles d’opération
• H04W 12/033 - Protection de la confidentialité, p.ex. par chiffrement du plan utilisateur, p.ex. trafic utilisateur
• H04L 67/561 - Ajout de données fonctionnelles à l’application ou de données de commande de l’application, p.ex. métadonnées
• H04L 67/565 - Conversion ou adaptation du format ou du contenu d'applications
• H04L 9/08 - Répartition de clés
• H04L 9/14 - Dispositions pour les communications secrètes ou protégées; Protocoles réseaux de sécurité utilisant plusieurs clés ou algorithmes
• H04L 9/30 - Clé publique, c. à d. l'algorithme de chiffrement étant impossible à inverser par ordinateur et les clés de chiffrement des utilisateurs n'exigeant pas le secret

Abrégé

The invention relates to a method for determining at least one container information (coi) about a laboratory sample container (1), wherein the method comprises the steps: a) acquiring an image (ibc) comprising a brightness and/or color information (bci) of a possible region (2) of the container (1), b) acquiring a map (md) comprising a depth information (di) of the region (2), and c) determining the container information (coi) by fusing the brightness and/or color information (bci) and the depth information (di).

Classes IPC  ?

• G06V 10/80 - Fusion, c. à d. combinaison des données de diverses sources au niveau du capteur, du prétraitement, de l’extraction des caractéristiques ou de la classification

Abrégé

The invention relates to novel HIV gp41 antigen compositions that are suitable for detecting antibodies against HIV in an isolated biological sample providing high specificity immunoassay results. It further relates to methods detecting HIV antibodies, use of novel HIV gp41 antigen compositions in immunoassays as well as to reagent kits comprising novel HIV gp41 antigen compositions.

Classes IPC  ?

• C07K 14/16 - HIV-1
• G01N 33/569 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour micro-organismes, p.ex. protozoaires, bactéries, virus

Abrégé

A position tracking system (112) for tracking a relative position between at least two connected modules (114) is disclosed. The position tracking system (112) comprises: - at least one target (118) associated with a first one of the at least two connected modules (114), wherein the at least one target (118) is at least one of arrangeable on and arrangeable within the first one of the at least two connected modules (114), wherein the at least two connected module (114) are mechanically interacting entities and/or components, configured for allowing transport of objects from one module to the other module; - at least one position sensor (120) associated with a second one of the at least two connected modules (114), wherein the position sensor (120) is configured for generating at least one sensor signal according to a relative position between the at least one position sensor (120) and the at least one target (118), wherein the at least one position sensor (120) is at least one of arrangeable on and arrangeable within the second one of the at least two connected modules (114); - at least one processing unit (122) configured for tracking a relative position between the connected modules (114) from the at least one sensor signal in at least one plane (124); and - at least one further sensor (140) configured for generating a further sensor signal according to at least one further parameter, wherein the further sensor (140) is selected from the group consisting of: a temperature sensor (142) and/or a humidity sensor, wherein the processing unit (122) is further configured for considering the at least one further sensor signal when determining the relative position between the connected modules (114). Further disclosed are a monitoring system (110) for monitoring at least two connected modules (114), method for tracking a relative position between at least two connected modules (114) by using at least one position tracking system (112) and a method for monitoring at least two connected modules (114) by using at least one monitoring system (110).

Classes IPC  ?

• G01N 35/00 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes ; Manipulation de matériaux à cet effet
• G01N 35/04 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes ; Manipulation de matériaux à cet effet en utilisant une série de récipients à échantillons déplacés par un transporteur passant devant un ou plusieurs postes de traitement ou d'analyse - Détails du transporteur

Abrégé

The present invention relates to in vitro methods for aiding in the detection of hepatocellular carcinoma (HCC) in a subject comprising determining the amount of one or more glycan structure at position N207 of haptoglobin (i.e. of the B-chain of haptoglobin having the sequence given in SEQ ID NO: 1) in a sample obtained from said subject. Also disclosed are a glycan structure as well as a glycopeptide comprising said glycan structure, both of great utility in the detection of HCC. Further, the present invention relates to the use of one or more glycan structure at position N207 or of a glycopeptide comprising N207 of haptoglobin in combination with AFP and/or PIVKA in the detection of HCC.

Classes IPC  ?

• G01N 33/574 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour le cancer

Abrégé

A method of separating stereoisomers of N-phthaloyl-glutamic acid is described. The method comprises passing a solution comprising an L/D stereoisomer mixture of N-phthaloyl-glutamic acid through a chiral chromatography column by normal phase chromatography, wherein the chiral chromatography column comprises, as a stationary phase, silica having groups represented by formula (1) as described herein covalently bonded to a surface thereof.

Classes IPC  ?

• B01D 15/32 - Chromatographie en phase liée, p.ex. avec une phase normale liée, une phase inverse ou une interaction hydrophobe
• B01D 15/38 - Adsorption sélective, p.ex. chromatographie caractérisée par le mécanisme de séparation impliquant une interaction spécifique non couverte par un ou plusieurs des groupes , p.ex. chromatographie d'affinité, chromatographie d'échange par ligand ou chromatographie chirale
• B01J 20/24 - Composés macromoléculaires d'origine naturelle, p.ex. acides humiques ou leurs dérivés
• B01J 20/29 - Phases chirales
• B01J 20/289 - Phases reliées chimiquement à un substrat, p.ex. à de la silice ou à des polymères reliées par l'intermédiaire d'un espaceur
• B01J 20/285 - Absorbants ou adsorbants poreux à base de polymères
• C12P 13/14 - Acide glutamique; Glutamine

Abrégé

The present invention relates to in vitro methods for aiding in the detection of hepatocellular carcinoma (HCC) in a subject. The method may comprise determining the amount of one or more N-glycan structure attached to haptoglobin (i.e. of the β- chain of haptoglobin having the sequence given in SEQ ID NO: 1) in a sample obtained from said subject and comparing the amount of said one or more glycan structure to a reference amount of said one or more glycan structure, wherein an altered amount of said one or more glycan structure in said patient sample relative to the reference amount of said one or more glycan structure is indicative for HCC. Further, the present invention relates to the use of one or more glycan structure attached to haptoglobinor of a glycopeptide derived from haptoglobin in combination with AFP and/or PIVKA-II in the detection of HCC.

Classes IPC  ?

• G01N 33/574 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour le cancer

Abrégé

The present invention relates to a method for assessing whether a subject has experienced one or more silent infarcts in a subject, said method comprising a) determining the amount of the biomarker ESM-1 in a sample from the subject, b) comparing the amount determined in step a) to a reference, and c) assessing whether a subject has experienced one or more silent infarcts. The present invention further relates to a method for predicting silent infarcts and/or cognitive decline, and methods for assessing and monitoring of the extent of silent small and large noncortical and cortical infarcts in a subject. Further encompassed by the present invention are the corresponding uses.

Classes IPC  ?

• G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

The present invention relates to an antibody or an antigen binding fragment thereof that specifically binds to α-1,6-core-fucosylated prostate specific antigen (PSA) and partial sequences thereof comprising the α-1,6-core-fucose residue. The antibodies and antigen binding fragments significantly discriminate between core-fucosylated PSA or core-fucosylated PSA partial sequences and other glycosylated PSA species and partial sequences thereof lacking the core-fucose residue, including aglycosylated PSA, as well as core-fucosylated glycan in other contexts. The present invention further relates to nucleic acid molecules encoding the light chain variable region or the heavy chain variable region of the antibody of the invention, as well as vectors comprising said nucleic acid molecules. The invention also relates to a host cell comprising the vector(s) of the invention, as well as to methods for the production of an antibody or antigen binding fragment of the invention comprising culturing the host cell of the invention under suitable conditions and isolating the antibody produced. Furthermore, the present invention relates to an antibody obtainable by the method of the invention, to a composition comprising at least one of the antibody or antigen binding fragment of the invention, the nucleic acid molecule of the invention, the vector of the invention, the host cell of the invention or the antibody produced by the method of the invention. The present invention also relates to the use of an antibody or antigen binding fragment of the invention for detecting and discriminating core-fucosylated PSA or core-fucosylated partial sequences thereof in biological samples.

Classes IPC  ?

• C07K 16/30 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
• G01N 33/574 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour le cancer
• G01N 1/30 - Teinture; Imprégnation

Abrégé

An automatic analyzer is capable of reducing the time required for a series of maintenance operations in that the user’s maintenance work is linked to the device driving so that the maintenance work proceeds in the order of the maintenance work tools. An automatic analyzer includes a plurality of processing units for processing a specimen: an agitation mechanism, a reagent dispensing mechanism, a mixer, an incubator, and a specimen dispensing mechanism. A control unit controls a processing unit, an analysis unit, and a display unit and causes the display unit to display a plurality of maintenance work tools used for maintenance work performed by the operator on the plurality of processing units and to display the maintenance work contents of the plurality of processing units that continuously use one of the plurality of maintenance work tools, selected by the operator via the display unit.

Classes IPC  ?

• G01N 35/02 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes ; Manipulation de matériaux à cet effet en utilisant une série de récipients à échantillons déplacés par un transporteur passant devant un ou plusieurs postes de traitement ou d'analyse
• G01N 35/10 - Dispositifs pour transférer les échantillons vers, dans ou à partir de l'appareil d'analyse, p.ex. dispositifs d'aspiration, dispositifs d'injection
• G01N 35/00 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes ; Manipulation de matériaux à cet effet

Abrégé

The present invention relates to a method, a diagnostic system, a kit and the use thereof for efficiently detection of an analyte of interest by nanoESI mass spectrometry.

Classes IPC  ?

• G01N 33/58 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des substances marquées
• G01N 33/74 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des hormones

Abrégé

The present invention relates to a method for providing a verified analyte measurement of a sample with a chromatography mass spectrometer device, said method comprising the following steps: a) admixing an interferent monitoring compound and, optionally an internal standard, to the sample; b) determining a chromatogram of the sample by acquiring a plurality of data points for signal intensities over time for said interferent monitoring compound, said analyte, and optionally said internal standard; and c) comparing a property of an interferent monitoring compound peak to a property of an internal standard peak and/or to a property of an analyte peak; and to methods and systems related thereto.

Classes IPC  ?

• G01N 33/96 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir un étalon de contrôle du sang ou du sérum
• G01N 30/88 - Systèmes intégrés d'analyse, spécialement adaptés à cet effet, non couverts par un seul des groupes
• G01N 33/74 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des hormones
• G01N 30/72 - Spectromètres de masse
• G01N 30/86 - Analyse des signaux

Abrégé

The present invention relates to a method for detecting and/or quantifying an analyte in a sample using mass spectrometry. The method of the invention comprises: extracting the analyte from the sample using solid phase extraction (SPE) so as to obtain an SPE extract comprising the analyte, concentrating the analyte, said concentrating comprising evaporating solvent from the SPE-extract; and detecting and/or quantifying the analyte in the sample using mass spectrometry.

Classes IPC  ?

• G01N 30/12 - Préparation par évaporation
• G01N 30/72 - Spectromètres de masse

Abrégé

The present invention relates to a method for detecting and/or quantifying one or more steroids using mass spectrometry, said steroids comprising at least one 11-oxygenated steroids. The method of the invention comprises (i) extracting the one or more steroids from the sample using solid phase extraction (SPE) so as to obtain an SPE extract comprising the one or more steroids; (ii) concentrating the one or more steroids, said concentrating comprising evaporating solvent from the SPE-extract; and (iii) detecting or quantifying the one or more steroids in the sample using mass spectrometry.

Classes IPC  ?

• G01N 33/74 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des hormones
• G01N 30/72 - Spectromètres de masse

Abrégé

The present invention relates to a method for determining at least one analyte of interest. The present invention further relates to a kit, a complex, a method to synthesize a complex and the use thereof for detecting the analyte of interest in the sample.

Classes IPC  ?

• G01N 33/533 - Production de composés immunochimiques marqués avec un marqueur fluorescent
• G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
• C07F 15/02 - Composés du fer

Abrégé

A method for optimizing at least one parameter setting of at least one mass spectrometry device (110) operating at unit resolution is disclosed. The method comprises the following steps: a) determining at least one analyte detection window for detecting an analyte of interest with the mass spectrometry device (110), wherein the analyte detection window is defined by a central mass to charge ratio value of the analyte and a predefined width, wherein the central mass to charge ratio value of the analyte is set to a theoretical mass to charge ratio value of the analyte of interest having more than one decimal place and/or a mass to charge ratio value of the analyte of interest determined by a high resolution mass spectrometry measurement having more than one decimal place; b) determining at least one internal standard detection window for detecting an internal standard substance with the mass spectrometry device (110), wherein the internal standard detection window is defined by a central mass to charge ratio value of the internal standard substance and the pre-defined width, wherein the central mass to charge ratio value of the internal standard substance is set to a mass to charge ratio value of the internal standard substance calculated relative to the analyte of interest and having more than one decimal place and/or to a mass to charge ratio value of the internal standard substance determined by a high resolution mass spectrometry measurement having more than one decimal place.

Classes IPC  ?

• H01J 49/00 - Spectromètres pour particules ou tubes séparateurs de particules
• H01J 49/06 - Dispositifs électronoptiques ou ionoptiques

Abrégé

The present invention relates to compounds which are suitable to be used in mass spectrometry as well as methods of mass spectrometric determination of analyte molecules using said compounds.

Classes IPC  ?

• G01N 33/58 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des substances marquées

Abrégé

A Reagent container cap (116) is adapted to being mounted to a reagent container and to being adjustable, at least after an initial opening of the cap (116), between an opened state and a closed state, wherein the reagent container cap (116) defines a cap interior space (109) and has a cap opening (116o) allowing access to the cap interior space (109) from above when the cap (116) is in the opened state; and wherein, in the closed state of the cap (116), the cap interior space (109) is open only towards a bottom side (116b), wherein the reagent container cap (116) comprises a main portion (116m) and an insert portion (116i) that are fixedly connected to each other and made from different materials, wherein, when the cap (116) is in the closed state, the cap interior space (109) comprises a region (109t) which is delimited circumferentially and towards the upper side of this region completely and exclusively by surfaces of the insert portion (116i).

Classes IPC  ?

• B01L 3/00 - Récipients ou ustensiles pour laboratoires, p.ex. verrerie de laboratoire; Compte-gouttes

Abrégé

A reaction vessel for a diagnostic analyzer comprising a plurality of processing stations. The reaction vessel comprises at least one sensor configured to measure at least one physical parameter associated with at least one of the processing stations of the diagnostic analyzer when disposed at the at least one of the processing stations, a memory configured to at least temporarily store at least one measurement value indicating the physical parameter provided by the sensor, a processing unit configured to control the sensor and to output measurement data including the measurement value from the memory, an interface configured to provide communication of the processing unit with an external electronic device, a power source configured to supply electric power to the sensor, the processing unit and the memory. The reaction vessel defines an internal volume. The sensor, the processing unit, the memory and the interface are arranged within the internal volume.

Classes IPC  ?

• B01L 3/00 - Récipients ou ustensiles pour laboratoires, p.ex. verrerie de laboratoire; Compte-gouttes

Abrégé

The present invention relates to methods for assessing whether or not a patient has aggressive prostate cancer by determining the levels of particular glycoforms attached to prostate specific antigen (PSA) protein in a biofluid sample of a subject, and comparing the determined level or concentration to a reference. The methods are particularly useful for assessing subjects that have 2-10 ng/ml total PSA in the subject's serum.

Classes IPC  ?

• G01N 33/574 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour le cancer

Abrégé

An automated method of calibrating a sensor located in a flow-through sensor path and requiring at least one oxygenated calibration fluid for calibration comprises transporting a predefined amount of deoxygenated calibration fluid from a fluid supply into a fluidic line between a fluid-selection valve and the sensor path, transporting ambient air into the fluidic line before and after transporting the calibration fluid forming an isolated plug of calibration fluid between zones of ambient air, oscillating the calibration fluid plug back and forth within a predefined length of the fluidic line causing reciprocating fluid film tailing along the inner walls of the fluidic line, and facilitating oxygenation of the calibration fluid via oxygen uptake by the fluid film from the ambient air in the fluidic line, and transporting the oxygenated calibration fluid into the sensor path at a position where the sensor is located and calibrating the sensor.

Classes IPC  ?

• A61B 5/1495 - Mesure des caractéristiques du sang in vivo, p.ex. de la concentration des gaz dans le sang, de la valeur du pH du sang Étalonnage ou test des sondes in vivo
• A61B 5/145 - Mesure des caractéristiques du sang in vivo, p.ex. de la concentration des gaz dans le sang, de la valeur du pH du sang

Abrégé

The present invention relates to a method, a diagnostic system, a dopand and the use thereof for the enhancement of detection of an analyte of interest by Cross Spray ESI mass spectrometry.

Classes IPC  ?

• G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
• H01J 49/16 - Sources d'ions; Canons à ions utilisant une ionisation de surface, p.ex. émission thermo-ionique ou photo-électrique

Abrégé

The present invention relates to a method for assessing whether a subject has experienced one or more silent infarcts in a subject, said method comprising a) determining the amount of IGFBP7 in a sample from the subject, b) comparing the amount determined in step a) to a reference, and c) assessing whether a subject has experienced one or more silent infarcts. The present invention further relates to a method for predicting silent infarcts and/or cognitive decline, and methods for assessing and monitoring of the extent of silent small and large noncortical and cortical infarcts in a subject. Further encompassed by the present invention are the corresponding uses.

Classes IPC  ?

• G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

The present invention relates to an in vitro method for assessing cholangiocarcinoma in a patient sample, comprising the steps of: a) determining the level of tissue inhibitor of metalloproteinase-1 (TIMP1) in the patient sample, wherein the patient sample is selected from a group consisting of serum, plasma and whole blood sample from an individual, b) comparing the level of TIMP1 determined in step (a) with a reference level of TIMP1, and c) assessing cholangiocarcinoma in the patient sample by comparing the level determined in step (a) to the reference level of TIMP1, wherein an increased level of TIMP1 compared to the reference level of TIMP1 is indicative for cholangiocarcinoma in the patient sample. Further, the present invention relates to an in vitro method for assessing cholangiocarcinoma comprising TIMP1 and MMP2, the use of TIMP1 and optionally MMP2 in the in vitro assessment of CCA, and a kit for performing the said methods.

Classes IPC  ?

• G01N 33/574 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour le cancer

Abrégé

The present disclosure refers to a sensor assembly for an IVD analyzer, the sensor comprising two opposite substrates with at least one fluidic conduit for receiving a sample. The electrodes of different types of electrochemical sensors are arranged on the two opposite substrates facing the at least one fluidic conduit for coming in contact with the sample and determining sample parameters, wherein the counter electrodes and the reference electrodes are formed on one substrate and the working electrodes are formed on the opposite substrate. This achieves optimal sensor-working conditions in terms of a homogeneous and symmetrical electric field density and enables a sensor assembly with simpler geometry and smaller size.

Classes IPC  ?

• G01N 27/06 - Recherche ou analyse des matériaux par l'emploi de moyens électriques, électrochimiques ou magnétiques en recherchant l'impédance en recherchant la résistance d'un liquide
• G01N 33/487 - Analyse physique de matériau biologique de matériau biologique liquide

Abrégé

The present invention relates to a method for assessing whether a subject has experienced one or more silent infarcts in a subject, said method comprising a) determining the amounts of the biomarkers Osteopontin, cardiac Troponin, a natriuretic peptide and FABP-3 in a sample from the subject, b) comparing the amounts determined in step a) to references, and c) assessing whether a subject has experienced one or more silent infarcts. The present invention further relates to a method for predicting silent infarcts and/or cognitive decline, and methods for assessing and monitoring of the extent of silent small and large noncortical and cortical infarcts in a subject. Further encompassed by the present invention are the corresponding uses.

Classes IPC  ?

• G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

The present invention relates to a method for assessing myocardial infarction comprising the steps of determining the amount of a first biomarker in a sample of a subject, said first biomarker being a cardiac Troponin, determining the amount of a second biomarker in a sample of the subject, wherein said second biomarker is selected from the group consisting of: a BMP 10-type peptide (Bone Morphogenic Protein 10-type peptide), FGF23 (Fibroblast growth factor 23), a BNP -type peptide, cardiac myosin binding protein C (cMyBPC) and ANG2 (Angiopoietin 2), comparing the amounts of the biomarkers to references for said biomarkers and/or calculating a score for assessing myocardial infarction based on the amounts of the biomarkers, and assessing said subject based on the comparison and/or the calculation. The invention also relates to the use of a first biomarker being a cardiac Troponin and a second biomarker selected from the group consisting of: a BMP 10-type peptide (Bone Morphogenic Protein 10-type peptide), FGF23 (Fibroblast growth factor 23), a BNP -type peptide, cardiac myosin binding protein C (cMyBPC) and ANG2 (Angiopoietin 2), or at least one detection agent for said first biomarker and at least one detection agent for said second biomarker for assessing myocardial infarction. Moreover, the invention further relates to a computer-implemented method for assessing myocardial infarction and a device and a kit for assessing myocardial infarction.

Classes IPC  ?

• G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

The present invention relates to a method for assessing myocardial infarction comprising the steps of determining the amount of a first biomarker in a sample of a subject, said first biomarker being cMyBPC, determining the amount of a second biomarker in a sample of the subject, wherein said second biomarker is selected from the group consisting of: a BMP10- type peptide (Bone Morphogenic Protein 10-type peptide), FGF23 (Fibroblast growth factor 23), a BNP-type peptide (Brain natriuretic peptide type peptide), GDF-15 (Growth differentiation factor 15), ANG2 (Angiopoietin 2), CRP (C-reactive protein), ESM1 (endothelial cell specific molecule 1), or a lipid biomarker, such as Cholesterol, LDL (Low Density Lipoprotein) or APOAT (Apolipoprotein A-1) comparing the amounts of the biomarkers to references for said biomarkers and/or calculating a score for assessing myocardial infarction based on the amounts of the biomarkers, and assessing said subject based on the comparison and/or the calculation. The invention also relates to the use of a first biomarker being cMyBPC and a second biomarker selected from the group consisting of: a BMP10-type peptide, FGF23, a BNP-type peptide, GDF15, ANG2, CRP (C-reactive protein), ESM1, or a lipid biomarker, such as Cholesterol or LDL, or at least one detection agent for said first biomarker and at least one detection agent for said second biomarker for assessing myocardial infarction. Moreover, the invention further relates to a computer-implemented method for assessing myocardial infarction and a device and a kit for assessing myocardial infarction.

Classes IPC  ?

• G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
• G01N 33/92 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des lipides, p.ex. le cholestérol

Abrégé

A computer-implemented method of providing user guidance for laboratory issue resolution within a laboratory system is presented. The method comprises monitoring activity by a user within a laboratory setting of the laboratory system by a user guidance system, detecting a laboratory issue within the laboratory system, retrieving by the user guidance system a preferred resolution to the detected laboratory issue and typical time to perform preferred solution from a database, notifying the user to the laboratory issue, detecting a non-preferred issue resolution for the laboratory issue being performed by the user, displaying the user guidance system to the user, wherein the user guidance system provides the retrieved preferred resolution for the laboratory issue to the user, resolving the laboratory issue by the user using the user guidance system, and removing or updating the display of the user guidance system following the resolution of the laboratory issue.

Classes IPC  ?

• G06Q 10/0631 - Planification, affectation, distribution ou ordonnancement de ressources d’entreprises ou d’organisations
• G06Q 10/0639 - Analyse des performances des employés; Analyse des performances des opérations d’une entreprise ou d’une organisation

Abrégé

The present invention includes: a reagent vessel holding part that holds a reagent vessel for accommodating a reagent; a reagent vessel information detection unit that detects information relating to the reagent vessel; a display unit that displays a screen including an operation region where operations from a user are received; and a control unit that causes the display unit to display the screen. The control unit has: a vessel presence/absence determination unit that determines whether the reagent vessel is present in the reagent vessel holding unit on the basis of the information detected by the reagent vessel information detection unit; a first operation region output unit that outputs, to the screen, a first operation region which is operated when the user has confirmed removal of the reagent vessel; a second operation region output unit that outputs, to the screen, a second operation region which is operated when shutdown is performed; and a warning output unit that outputs, to the screen, a warning prompting removal of the reagent vessel when the vessel presence/absence determination unit has determined that the reagent vessel is present. The foregoing makes it possible to provide an automated analysis device which prevents shutdown from starting while a reagent has been left behind.

Classes IPC  ?

• G01N 35/00 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes ; Manipulation de matériaux à cet effet

Abrégé

A handheld diagnostic device, specifically for point-of-care applications. The handheld diagnostic device comprises at least one diagnostic measurement unit configured for performing at least one diagnostic measurement, the diagnostic measurement unit comprising at least one test element port for determining at least one diagnostic parameter of at least one patient by using at least one diagnostic test element; at least one camera configured for capturing at least one image of at least one wound of the patient; and at least one control unit, the control unit being configured for controlling the diagnostic measurement and for controlling the capturing of the image of the wound, wherein the control unit is further configured for storing at least one measurement result of the diagnostic measurement and the at least one image in at least one database record of the patient. A diagnostic system and a diagnostic method are further disclosed.

Classes IPC  ?

• A61B 5/00 - Mesure servant à établir un diagnostic ; Identification des individus
• G16H 30/20 - TIC spécialement adaptées au maniement ou au traitement d’images médicales pour le maniement d’images médicales, p.ex. DICOM, HL7 ou PACS
• A61B 5/0205 - Evaluation simultanée de l'état cardio-vasculaire et de l'état d'autres parties du corps, p.ex. de l'état cardiaque et respiratoire

Abrégé

The present invention relates to a method for determining the presence or level of an analyte of interest and the use thereof. Further, present invention relates to an analytical system, a sampling tube and the use of the sampling tube and a nucleophilic derivatization reagent.

Classes IPC  ?

• G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
• G01N 33/543 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
• G01N 33/94 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des narcotiques
• G01N 30/72 - Spectromètres de masse